Treatment of Drug Resistant Epilepsy (Cannabidiol)
Physician Expanded Access to Investigational New Drug Cannabidiol for the Treatment of Drug Resistant Epilepsy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Flordia CRC
-
Miami, Florida, United States, 33155
- Nicklaus Children's Hospital, Miami Children's Health System
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- history of a trial of at least four drugs, including one trial of a combination of two concomitant drugs, without successful seizure control.
- Vagal nerve stimulation: VNS must be on stable settings for a minimum of 1 month,
- RNS deep brain stimulation, or
- the ketogenic diet can be considered equivalent to a drug trial and must be on a stable ratio for a minimum of 3 months.
- anti-epileptic drugs at stable doses for a minimum of 4 weeks prior to enrollment.
- 4 clinically countable seizures per month: Seizure history to include a documented history of generalized seizures (drop attacks, atonic, tonic-clonic and/or myoclonic), focal seizures without loss of consciousness with a motor component, focal seizures with loss of consciousness, or focal seizures with secondary generalization,
Exclusion Criteria:
- Use of CBD based product within the previous 30 days.
- Initiation of felbamate within 6 months.
- Allergy to CBD or any cannabinoid.
- Unable to comply with study visits/requirements.
- Diagnosis of Dravet Syndrome or Lennox-Gastaut syndrome will be excluded completely from this trial.
- Cannabidiol is contraindicated in pregnancy. Female subjects who are pregnant will be excluded from the study. If a female subject is able to become pregnant, she will be given a serum pregnancy test before entry into the study. Female subjects will be informed not become pregnant while taking cannabidiol. Female subjects must tell the investigator and consult an obstetrician or maternal-fetal specialist if they become pregnant during the study.
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Steven Winesett, MD, University of Florida
Study record dates
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IRB201401013
- FLGV (Other Grant/Funding Number: Florida Department of Health)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.